The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

We continue to see turning Kyowa Hakko Bio into profitability as a priority to restore the market’s confidence in its strategic pivot to health science expansion. Kirin bought a 30% stake in ...

Narrow-moat Kirin posted mixed first-quarter results with solid growth in the domestic brewery, US soft beverage, and pharmaceutical businesses but deteriorating profitability of Kyowa Hakko Bio ...

Kyowa Kirin is a Japanese pharmaceutical company created by the merger of Kyowa Hakko and Kirin Pharma in 2008. Known for its antibody-based treatments, the current key earnings driver is its ...

Being part of Kirin Holdings, Kyowa Hakko has a distinct edge as it can leverage years of expertise and technical know-how of its parent company. In terms of ensuring higher product quality ...

Kyowa Kirin is a Japanese pharmaceutical company created by the merger of Kyowa Hakko and Kirin Pharma in 2008. Known for its antibody-based treatments, the current key earnings driver is its ...

NEW YORK — Kyowa Hakko Bio Co., Ltd., a subsidiary of Kirin Holdings Co., Ltd., Tokyo, launched Immuse, a novel dietary supplement ingredient, in the United States. Immuse is a patented ...

Ultragenyx Pharmaceutical Inc. and partner Kyowa Hakko Kirin Co. Ltd. (KHK) have won FDA approval for Crysvita (burosumab), making it the first U.S.-approved treatment for X-linked hypophosphatemia ...

TOKYO -- Japan's Kyowa Hakko Kirin expects to more than double its operating profit by 2020, using a breakthrough drug to expand business in profitable overseas markets. The drugmaker targets ...

TOKYO, Dec. 11, 2017 /PRNewswire/ -- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that the results of the Global Phase 3 study ...

TOKYO--(BUSINESS WIRE)--Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151) (President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announces that the U.S. Food and Drug Administration (FDA ...